Agilent and EQT, the Sweden-based private equity group, has signed a definitive agreement for Agilent to acquire Dako, the Denmark-based cancer diagnostic company. The $2.2 billion acquisition (on a debt-free basis) is the largest in Agilent’s history.
Dako provides antibodies, reagents, scientific instruments and software primarily to customers in pathology laboratories. The acquisition is expected to close within the next 60 days, subject to the satisfaction of customary closing conditions.
Credit Suisse Securities was Agilent’s exclusive financial advisor in the transaction.
[Image Courtesy: Agilent]